Zacks Research Brokers Boost Earnings Estimates for IOVA

Key Points

• Zacks Research raised its Q1 2026 EPS estimate for Iovance to ($0.20) from ($0.21) and issued multi-year loss forecasts including Q2 2027 at ($0.13), Q1 2028 at ($0.09) and FY2028 at ($0.19), while the consensus full‑year loss remains ($1.24) per share.
• Analyst coverage is mixed—six Buys, four Holds and two Sells—with an average rating of Hold and an average price target of $8.88; several firms raised targets (Barclays to $11, UBS to $4) while Goldman retained a $2 Sell.
• Iovance recently topped quarterly expectations (EPS $0.18 vs. consensus -$0.22; revenue $86.77M vs. $81.61M), trades near $4.01 with a $1.65B market cap, and is ~77% institutionally owned after notable stake increases by Vanguard, State Street and Goldman.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Equities researchers at Zacks Research boosted their Q1 2026 EPS estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, April 8th. Zacks Research analyst Team now expects that the biotechnology company will earn ($0.20) per share for the quarter, up from their prior estimate of ($0.21). The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($1.24) per share. Zacks Research also issued estimates for Iovance Biotherapeutics' Q2 2027 earnings at ($0.13) EPS, Q1 2028 earnings at ($0.09) EPS and FY2028 earnings at ($0.19) EPS.

A number of other research analysts have also weighed in on the company. Citizens Jmp raised Iovance Biotherapeutics from a "market perform" rating to a "market outperform" rating and set a $5.00 price objective on the stock in a report on Tuesday, March 3rd. UBS Group lifted their price objective on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a "neutral" rating in a research note on Thursday, March 5th. Wall Street Zen upgraded shares of Iovance Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Barclays upped their price target on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. Finally, The Goldman Sachs Group reaffirmed a "sell" rating and set a $2.00 price target on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $8.88.

Iovance Biotherapeutics Price Performance

Shares of IOVA stock opened at $4.01 on Friday. The business has a fifty day moving average of $3.47 and a 200 day moving average of $2.75. Iovance Biotherapeutics has a 1 year low of $1.64 and a 1 year high of $5.63. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -3.58 and a beta of 0.76.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The business had revenue of $86.77 million during the quarter, compared to the consensus estimate of $81.61 million.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Iovance Biotherapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company's stock valued at $74,275,000 after buying an additional 3,148,096 shares during the period. State Street Corp raised its position in shares of Iovance Biotherapeutics by 51.5% in the fourth quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company's stock worth $55,041,000 after acquiring an additional 6,851,486 shares during the period. Invenomic Capital Management LP raised its position in shares of Iovance Biotherapeutics by 13.5% in the fourth quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company's stock worth $32,649,000 after acquiring an additional 1,417,897 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Iovance Biotherapeutics by 30.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company's stock worth $23,499,000 after acquiring an additional 2,032,062 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Iovance Biotherapeutics by 16.4% during the 4th quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company's stock worth $21,821,000 after acquiring an additional 1,123,337 shares in the last quarter. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.